Success Story

Peroxitech raises $25M Series A

Peroxitech Inc., announced the successful completion of a $25M Series A financing round that will advance its lead candidate, PIP-2, for the treatment of acute lung injury (ALI) into clinical development.  The company was launched in 2016 through the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures and founded by Dr. Aron Fisher from Penn Medicine. In addition to the first clinical indication, Peroxitech is also evaluating PIP-2 for several high unmet need areas where oxidative injury signaling pathways are a major contributor to disease progression.

Skip to content